Wifts Investment Group

An Investment Club


November 2009 Portfolio Update

nov09 update

For the month of November, Wifts Investment Club returned 1.00% comapred to 5.74% of S&P500. The portfolio underperformed the S&p500 by 4.74%.

FRX led the biggest gainer with 10.81% followed by BAC and DD with 8.71% and 8.67 respectively. JNJ was also up by 6.42%.

Biggest decliners were ACET which was down 5.53% followed by OME down 5.53%. AMN, which is our largest holding with about 12% of our portfolio, was down 3.42%.

November was a pretty quiet month for us. We did not make any transaction. However, due to new contributions our cash position has gone up to 14.63%.

Partnership NAV for the month ending November was $9.524.

No Comments

On Markets, Volume and Vampires

O Em Gee! Last Friday was quite amusing! By day, treasury yields pushed into the red (that sounds rather boring, actually) and by night, the vampires and werewolves of the Twilight saga “New Moon” sank their teeth deep into the already lean allowance of too many ingenuous, unsuspecting teenagers across America. In the battle of parents paying the government to keep their cash safe and their kids turning around to spend their cash to see half-naked bodies of Edward and Jake, it is safe to say Hollywood won.

But let’s talk about a loser here, for a change. The real loser ever since March this year has been the trading volume in equities. If you pull up any chart for a broad market index or ETF (^DJI, SPY etc), it’s hard to miss that trading volume has steadily declined, except in October when we saw a small relative rise. This meant not so great trading conditions for short-term traders who look to score big during times of high volume, which translates into high volatility and liquidity. Barring a few names, the October earning season did little to bring stocks into spotlight for volatile trading. When real volume dries up, algorithmic trading or computer programs take control. Many traders prefer to stay clear of these conditions because risk to reward scenarios are not very clear and attractive. To hit home the idea of just how inactive the market is, let me make a confession: I am writing this at work, and it’s not even lunch time.

It seems 2009 is as good as over. Investors are very risk-averse. Especially institutions that caught the rally and are now sitting in profits do not want to risk ending the year with losing trades. So they are sitting tight on the sidelines or stepping away from equities and into safer havens like Treasurys and corporate bonds. Obviously, you want to end the year with a bang, not with a whimper.

And this is where the earlier note about negative yields comes into play. When price goes up, yields come down. It so happens that people right now are so eager to buy short-term treasurys, called treasury bills, that by way of high demand, their price went up significantly enough to push their yields into the negative. On Friday, the yields registered a -.03%. Effectively, this means investors were willing to pay the government .03% interest to keep their cash safe. Tell me this isn’t amusing!

To me, this is so amusing I believe it beats vampire movies hands down. Unless, of course, the director pays me .03% of his ticket sales to change my mind.

No Comments

Health care as the favorite sector

I guess we are not the only ones who like heath care sector. This marketplace story says that on a poll of 150 fund managers, 15% “cited healthcare as their favorite sectors looking into 2010, slightly topping the 12% who listed technology.” As I have mentioned before, healthcare is our largest holding with about 26% of our asset. Our exposure to heathcare includes traditional pharmaceuticals such as FRX and JNJ, biotech companies (OSIP, CTIC) and a healthcare service provider (KND).

http://www.marketwatch.com/story/poll-fund-managers-favor-health-care-investments-2009-11-05?siteid=rss&rss=1

No Comments

October 2009 Portfolio Update

OCT09

In October, our portfolio returned -5.71% compared to -1.98% of S&P500. This means our portfolio underperformed S&P500 by 3.73%. Even with around 25% in cash for the most of the month, it managed to go down that much. This is a good reminder to everyone that we are in a risky business.

Since the portfolio was down, let’s start with the biggest loser. CTIC was down 22.76% in October for no particular reason. Nothing has changed since we first bought CTIC, so we were able to average down our purchase price to $1.23. Seems like October was not a good month for healthcare sector overall, probably because of the on going healthcare debate. FRX was down 9.4% and OSIP was down 8.72%. Another biggest decliner was OME, which dropped 14.22%, also for no particular reason. Small cap stocks are really volatile and they don’t always follow the overall market. Nothing to panic here.

Among the significant gainers were LMIA, up 7.37% and ADM which was up 3.08%. During the month of October, oil prices kept going up and so did our holding of BHI and XES. With oil above $80 per barrel, we decided to sell BHI at $47.25 for a gain of 58.8% without counting any dividends. We don’t think oil will go any higher than this any time soon. But just in case it does, we still have about 5% exposure to oil and energy sector with XES.

In other transactions, we have added two more positions to our holdings, AMN and ACET.  If you read the previous post, we had sold AMN at $85, but since then it has been falling down. We picked up quite a bit at $62 and it is now our largest holding at about 11.2% of total. We still have the price target for AMN at around $85. Aceto Corp (ACET) supplies chemicals for pharmaceutical and agricultural industry. We thought it was undervalued at $5.44, our purchase price.  Our price target for ACET is $8.50. ACET makes 5.25% of our portfolio.

We have used up some cash this month on those transactions. We now have 13.15% cash.

NAV of our partnership for the month ending October is $9.43.

No Comments

Septemeber 2009 Portfolio Update

sep09update

We have decided that from now on we”ll post a monthly update of our portfolio at the end of the month. To add credibility to the updates, we have signed up for covestor.com account, which links directly to the brokerage account and pulls out the holdings and trades that we have made. Unfortunately, covestor does not provide any performance information before the date we signed up with them, so everything that is calculated is since that date, which is September 3rd, 2009.

In September, our portfolio was up 10.49%, compared to S&P500’s 6.27%. Big mover was Ameron International (AMN), which went all the way up to $89 and we sold all of our holding at $85 for total gain of 51.8%. It has now dropped back in the range of $70.

AAR Corp (AIR) has been doing well after it released a strong quarterly report. It went up more than 30% in September. On the other hand, Cell Therapeutics (CTIC) is down 20% for us.

We decided to sell 75% of our holding in Kindred healthcare (KND) at $16.4 for a gain of 39.2%. The S&P500 was at the highest level for the year in mid-September and we wanted to build some cash. Now our portfolio is 25.08% in cash. Healthcare is still our biggest exposure with 24% of our portfolio invested in it.

Also new this month is the NAV of our partnership. We have decided to switch to NAV system so that it is easier to track individual’s contribution. September’s NAV is set at $10.00 per partnership unit. We will also include the monthly NAV in our update.

No Comments